Extramedullary plasmacytoma of the liver is rare. Here, we report a case presenting with rupture of extramedullary plasmacytoma of the liver. She had a past history of multiple myeloma with IgA lambda type. Her serum was positive for hepatitis C virus infection and exhibited elevated levels of serum protein induced by vitamin K absence or antagonist-II. She was initially diagnosed as rupture of hepatocellular carcinoma (HCC) and then treated with transarterial chemoembolization (TACE) since bloody ascites and formation of hematoma were seen around hyper-vascular liver tumors on computed tomography. However, the clinical course of this case after TACE was atypical for HCC rupture, as shown by the development of a huge intra-abdominal abscess extending from the liver tumor. Immuno-histochemical analysis of the tumor biopsy specimen revealed massive infiltration of plasma cells expressing IgA and lambda chain. To our knowledge, this is the first case of rupture of extramedullary liver plasmacytoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2169/internalmedicine.49.3103 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of Surgical Intervention in Treating Pathological Fractures of the Upper Extremity: A Retrospective Case Series.
Cureus
October 2024
Orthopedic Surgery, Kindai University Hospital, Osakasayama, JPN.
Background: We conduct a retrospective analysis of patients with pathological fractures resulting from upper extremity malignancies, focusing on the evaluation of treatment strategies employed.
Materials And Methods: We retrospectively studied 10 patients with metastatic bone tumors of the upper extremities. The study variables included tumor site, primary pathology, duration from the first diagnosis of the primary lesion to the occurrence of the pathological fracture, use of bone-modifying drugs, surgical technique, adjuvant therapy, postoperative functional assessment, Katagiri's score, American Society of Anesthesiologists physical status (ASA-PS), outcome, and correlations between the Eastern Cooperative Oncology Group Performance Status (ECOG-PS) and Musculoskeletal Tumor Society (MSTS) score.
[Extramedullary plasmacytoma of the liver: report of a case].
Zhonghua Bing Li Xue Za Zhi
October 2024
Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai 200438, China.
Case Report of Concomitant Diagnosis of Locally Advanced Intrahepatic Cholangiocarcinoma and Solitary Plasmacytoma of T11 Vertebra: Impact on Diagnostic and Clinical Management.
Curr Oncol
September 2024
IRIS GRIM-Site de Saint-Herblain-Santé Atlantique, F-44800 Saint-Herblain, France.
A solitary bone plasmacytoma is a rare tumor. Intrahepatic cholangiocarcinoma is the second most common primary liver cancer after hepatocellular carcinoma. We present the case of a 48-year-old female patient who consulted for recent back pain, with a final diagnosis of T10 solitary plasmacytoma and synchronous intrahepatic cholangiocarcinoma.
View Article and Find Full Text PDFExtraosseous Plasmacytomas: A Radiologist's Perspective-A Narrative Review of the Literature.
Diagnostics (Basel)
August 2024
Department of Radiology, General University of Patras, 61000 Patras, Greece.
Article Synopsis
- * EPs can appear in various body parts, including the lungs, breasts, and abdominal organs, making them tough to diagnose due to their similar imaging characteristics to other conditions.
- * The review highlights the importance of imaging for detecting EPs, but emphasizes that a histological confirmation is essential for an accurate diagnosis, especially for patients with a history of multiple myeloma, as timely diagnosis can greatly improve
PLAG1 interacts with GPX4 to conquer vulnerability to sorafenib induced ferroptosis through a PVT1/miR-195-5p axis-dependent manner in hepatocellular carcinoma.
J Exp Clin Cancer Res
May 2024
Department of Hepatobiliary Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Article Synopsis
- Sorafenib is a common first-line treatment for advanced hepatocellular carcinoma (HCC), but its effectiveness is limited; recent studies show it induces ferroptosis, a type of regulated cell death linked to iron and lipid peroxidation.
- Research revealed that the pleiomorphic adenoma gene 1 (PLAG1) contributes to HCC cells' resistance to ferroptosis induced by sorafenib by being regulated at the transcriptional level by the long non-coding RNA (lncRNA) PVT1.
- Analysis of 139 HCC patient samples found a significant correlation between PLAG1 and GPX4 levels, suggesting that PLAG1 helps maintain cellular redox balance and inhibits ferroptosis
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!